These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 28065411)

  • 1. Ki67 assessment in breast cancer: an update.
    Penault-Llorca F; Radosevic-Robin N
    Pathology; 2017 Feb; 49(2):166-171. PubMed ID: 28065411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of pathologic complete response and Ki67 expression after neoadjuvant chemotherapy in breast cancer.
    Yoshioka T; Hosoda M; Yamamoto M; Taguchi K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H
    Breast Cancer; 2015 Mar; 22(2):185-91. PubMed ID: 23645542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.
    Zhang A; Wang X; Fan C; Mao X
    Front Endocrinol (Lausanne); 2021; 12():687244. PubMed ID: 34803903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.
    Dowsett M; Nielsen TO; A'Hern R; Bartlett J; Coombes RC; Cuzick J; Ellis M; Henry NL; Hugh JC; Lively T; McShane L; Paik S; Penault-Llorca F; Prudkin L; Regan M; Salter J; Sotiriou C; Smith IE; Viale G; Zujewski JA; Hayes DF;
    J Natl Cancer Inst; 2011 Nov; 103(22):1656-64. PubMed ID: 21960707
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ki67--no evidence for its use in node-positive breast cancer.
    Andre F; Arnedos M; Goubar A; Ghouadni A; Delaloge S
    Nat Rev Clin Oncol; 2015 May; 12(5):296-301. PubMed ID: 25781576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.
    Şahin S; Işık Gönül İ; Çakır A; Seçkin S; Uluoğlu Ö
    Int J Surg Pathol; 2016 Oct; 24(7):607-13. PubMed ID: 27284123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for developing Ki67 as a useful biomarker in breast cancer.
    Denkert C; Budczies J; von Minckwitz G; Wienert S; Loibl S; Klauschen F
    Breast; 2015 Nov; 24 Suppl 2():S67-72. PubMed ID: 26283598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
    Yeo B; Dowsett M
    Breast; 2015 Nov; 24 Suppl 2():S78-83. PubMed ID: 26255746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunocytochemical results for HER2 and Ki67 in breast cancer touch-smear cell specimens are reliable.
    Morimoto M; Bando Y; Nakagawa M; Takechi H; Yoshida T; Honda J; Tadokoro Y; Moriya T; Sasa M; Tangoku A
    Breast Cancer; 2016 Jul; 23(4):577-82. PubMed ID: 25808597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki67 and proliferation in breast cancer.
    Pathmanathan N; Balleine RL
    J Clin Pathol; 2013 Jun; 66(6):512-6. PubMed ID: 23436927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
    Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
    JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers.
    Iwamoto T; Katagiri T; Niikura N; Miyoshi Y; Kochi M; Nogami T; Shien T; Motoki T; Taira N; Omori M; Tokuda Y; Fujiwara T; Doihara H; Gyorffy B; Matsuoka J
    Oncotarget; 2017 Apr; 8(16):26122-26128. PubMed ID: 28412725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value.
    Joshi S; Watkins J; Gazinska P; Brown JP; Gillett CE; Grigoriadis A; Pinder SE
    BMC Cancer; 2015 Jul; 15():546. PubMed ID: 26205655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients.
    Chen X; Zhu S; Fei X; Garfield DH; Wu J; Huang O; Li Y; Zhu L; He J; Chen W; Jin X; Shen K
    BMC Cancer; 2015 Oct; 15():822. PubMed ID: 26514283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly reproducible results of breast cancer biomarkers when analysed in accordance with national guidelines - a Swedish survey with central re-assessment.
    Ekholm M; Grabau D; Bendahl PO; Bergh J; Elmberger G; Olsson H; Russo L; Viale G; Fernö M
    Acta Oncol; 2015 Jul; 54(7):1040-8. PubMed ID: 25959664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.
    Nielsen TO; Leung SCY; Rimm DL; Dodson A; Acs B; Badve S; Denkert C; Ellis MJ; Fineberg S; Flowers M; Kreipe HH; Laenkholm AV; Pan H; Penault-Llorca FM; Polley MY; Salgado R; Smith IE; Sugie T; Bartlett JMS; McShane LM; Dowsett M; Hayes DF
    J Natl Cancer Inst; 2021 Jul; 113(7):808-819. PubMed ID: 33369635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
    Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
    J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression, assessment and significance of Ki67 expression in breast cancer: an update.
    Lashen AG; Toss MS; Ghannam SF; Makhlouf S; Green A; Mongan NP; Rakha E
    J Clin Pathol; 2023 Jun; 76(6):357-364. PubMed ID: 36813558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
    Penault-Llorca F; André F; Sagan C; Lacroix-Triki M; Denoux Y; Verriele V; Jacquemier J; Baranzelli MC; Bibeau F; Antoine M; Lagarde N; Martin AL; Asselain B; Roché H
    J Clin Oncol; 2009 Jun; 27(17):2809-15. PubMed ID: 19380452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.